LIGAND PHARMACEUTICALS INC (LGND) is a publicly traded company in the Unknown sector. Across all available filings, 27 corporate insiders have executed 1046 transactions totaling $329.1M, demonstrating a bearish sentiment with -$300.4M in net insider flow. The most recent transaction on Dec 31, 2025 involved a transaction of 8 shares valued at $765.
No significant insider buying has been recorded for LGND in the recent period.
No significant insider selling has been recorded for LGND in the recent period.
Based on recent SEC filings, insider sentiment for LGND is bearish with an Insider Alignment Score of 4/100 and a net flow of -$300.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at LIGAND PHARMACEUTICALS INC (LGND) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 27 insiders are actively trading LGND stock, having executed 1046 transactions in the past 90 days. The most active insider is John L. Higgins (Executive), who has made 143 transactions totaling $83.0M.
Get notified when executives and directors at LGND file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Espinoza Octavio | Chief Financial Officer | Other | 8 | $95.68 | $765 | C-Suite |
| Dec 16, 2025 | Espinoza Octavio | Executive | Option Exercise | 69 | $57.22 | $3.9K | |
| Dec 16, 2025 | Espinoza Octavio | Executive | Option Exercise | 285 | $63.62 | $18.1K | |
| Dec 16, 2025 | Espinoza Octavio | Executive | Option Exercise | 652 | $92.65 | $60.4K | |
| Dec 16, 2025 | Espinoza Octavio | Executive | Option Exercise | 181 | $103.42 | $18.7K | |
| Dec 16, 2025 | Espinoza Octavio | Executive | Option Exercise | 1,194 | $52.84 | $63.1K | |
| Dec 12, 2025 | Espinoza Octavio | Executive | Sale | 1,804 | $188.31 | $339.7K | |
| Dec 8, 2025 | Aryeh Jason | Executive | Option Exercise | 2,034 | $69.51 | $141.4K | |
| Dec 5, 2025 | Espinoza Octavio | Executive | Payment | 1,862 | $184.87 | $344.2K | |
| Dec 4, 2025 | C. Davis Todd | Executive | Gift | 130 | $N/A | $0 | |
| Dec 1, 2025 | W. Kozarich John | Executive | Sale | 92 | $197.72 | $18.2K | |
| Dec 1, 2025 | W. Kozarich John | Executive | Sale | 92 | $193.86 | $17.8K | |
| Dec 1, 2025 | W. Kozarich John | Executive | Sale | 179 | $194.76 | $34.9K | |
| Dec 1, 2025 | W. Kozarich John | Executive | Sale | 30 | $200.02 | $6.0K | |
| Dec 1, 2025 | W. Kozarich John | Executive | Sale | 23 | $199.22 | $4.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 307 | $314.7M | 81.1% |
Exercise(M) | 239 | $32.3M | 8.3% |
Payment(F) | 138 | $25.4M | 6.5% |
Purchase(P) | 82 | $14.3M | 3.7% |
Other(J) | 39 | $590.0K | 0.2% |
Award(A) | 221 | $282.3K | 0.1% |
Disposition(D) | 6 | $255.6K | 0.1% |
Gift(G) | 14 | $0 | 0.0% |
Insider selling pressure at LIGAND PHARMACEUTICALS INC has increased, with 27 insiders executing 1046 transactions across all time. Total sales of $314.7M significantly outpace purchases of $14.3M, resulting in a net outflow of $300.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.